provider image
Welcome! You’re in GoodRx for healthcare professionals. Now, you’ll enjoy a streamlined experience created specifically for healthcare professionals.
Skip to main content
Jaypirca Coupon - Jaypirca 100mg tablet

Jaypirca

pirtobrutinib
Used for Non-Hodgkin Lymphoma
Used for Non-Hodgkin Lymphoma

Jaypirca (pirtobrutinib) is a targeted therapy called Bruton’s tyrosine kinase (BTK) inhibitor. It's used to treat certain types of blood cancers, like mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). It’s not a first-choice medication for these cancers, but it might be an option for people who had already tried at least 2 other anticancer treatments. Jaypirca (pirtobrutinib) is convenient because it’s a tablet that you take by mouth daily. Some of the more common side effects of this medication include lower blood cell counts, tiredness, and muscle pain.

Reviewed by:
reviewer
Allison Baxley, PharmD, BCOP
reviewer
Connie Zheng, PharmD
Last reviewed on August 4, 2024
BasicsSide effectsPros & consPharmacist tipsFAQsWarningsDosageCostAlternativesImagesReferencesPricesMedicare
basics-icon

What is Jaypirca (pirtobrutinib)?

What is Jaypirca (pirtobrutinib) used for?

How Jaypirca (pirtobrutinib) works

There’s a pathway inside some cells called the Bruton tyrosine kinase pathway, that sends signals that tell cells to grow and divide. This pathway is particularly active in B-cell cancers, such as mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL).

Jaypirca (pirtobrutinib) is a Bruton’s tyrosine kinase (BTK) inhibitor. It blocks a specific protein in the Bruton tyrosine kinase pathway so that the cancer cells can’t grow or spread as well.

Drug Facts

Common BrandsJaypirca
Drug ClassBruton tyrosine kinase (BTK) inhibitor
Controlled Substance ClassificationNot a controlled medication
Generic StatusNo lower-cost generic available
AvailabilityPrescription only
coupon-save-icon

Get your GoodRx coupon

Avg retail price
$25195.64(save 8.88%)
GoodRx discount
$22957.34
See prices
basics-icon

What are the side effects of Jaypirca (pirtobrutinib)?

The following side effects may get better over time as your body gets used to the medication. Let your healthcare provider know immediately if you continue to experience these symptoms or if they worsen over time.

Common Side Effects

Note: Side effects listed were reported by people who took Jaypirca for MCL

Other Side Effects

  • Rash
  • Numbness
  • Cough
  • Constipation
  • Fever
  • Joint pain
  • Nausea
  • Stomach pain
  • Bleeding
  • Dizziness

Serious Side Effects

Contact your healthcare provider immediately if you experience any of the following.
  • Serious infections: fever, chills, cough, muscle aches, very fast heartbeat, severe tiredness
  • Serious bleeding: bruising that won't go away or bleeding that's difficult to stop, nosebleeds, blood in urine, blood in stool
  • Serious heart problems: irregular heartbeat, lightheadedness, passing out
  • Severe liver problems: tiredness, nausea, vomiting, stomach pain or tenderness, weight loss, dark urine, yellowing of the whites of the eyes or skin

Source: DailyMed

The following side effects have also been reported

Side effects that you should report to your care team as soon as possible:

  • Allergic reactions—skin rash, itching, hives, swelling of the face, lips, tongue, or throat
  • Bleeding—bloody or black, tar-like stools, vomiting blood or brown material that looks like coffee grounds, red or dark brown urine, small red or purple spots on skin, unusual bruising or bleeding
  • Heart rhythm changes—fast or irregular heartbeat, dizziness, feeling faint or lightheaded, chest pain, trouble breathing
  • Infection—fever, chills, cough, sore throat, wounds that don't heal, pain or trouble when passing urine, general feeling of discomfort or being unwell
  • Liver injury—right upper belly pain, loss of appetite, nausea, light-colored stool, dark yellow or brown urine, yellowing skin or eyes, unusual weakness or fatigue
  • Low red blood cell level—unusual weakness or fatigue, dizziness, headache, trouble breathing

Side effects that usually do not require medical attention (report these to your care team if they continue or are bothersome):

pros-and-cons

Pros and cons of Jaypirca (pirtobrutinib)

thumbs-up

Pros

Taken by mouth, so good for people who don’t like needles

Taken once daily

Doesn’t typically cause hair loss

thumbs-down

Cons

Interacts with some medications

Raises your risk of bleeding

Can raise your risk for serious infections

pharmacist-tips

Pharmacist tips for Jaypirca (pirtobrutinib)

pharmacist

  • You should swallow Jaypirca (pirtobrutinib) tablets whole. Do not crush, cut, or chew them. You can take this medication with or without food.

    • If you miss a dose of Jaypirca (pirtobrutinib) by more than 12 hours, skip it and start over with your next scheduled dose.

      • Let your oncology team know if you need any type of surgical procedure, such as having a tooth pulled or a biopsy, while you’re taking Jaypirca (pirtobrutinib). Because Jaypirca (pirtobrutinib) can raise your risk of bleeding, your care team might recommend you pause Jaypirca (pirtobrutinib) for a few days before and after your procedure.

        • Taking Jaypirca (pirtobrutinib) can raise your risk of infections. This is because this medication can lower white blood cell count, which can weaken your immune system. If you do get sick, your body will have a harder time fighting it off. You can help prevent infections by washing your hands often, avoiding crowds, and washing raw fruits and vegetables thoroughly before eating them.

          • Tell your oncology team before you start any new medications while you’re taking Jaypirca (pirtobrutinib). There are some medications that you should avoid taking with Jaypirca (pirtobrutinib) because they might affect the level of Jaypirca (pirtobrutinib) in your body, which can affect how well the medication works or affect your risk of side effects.

            • Ask your oncology team about the best way to handle and throw away Jaypirca (pirtobrutinib) safely. Anticancer medications can be harmful to people who handle or come in contact with them. Store Jaypirca (pirtobrutinib) in a safe place away from children and pets.

              • We don’t know if Jaypirca (pirtobrutinib) passes into human milk, but this medication could cause harm to a nursing infant. Because of this risk, you should avoid breastfeeding while taking Jaypirca (pirtobrutinib) and for 1 week after the last dose.

                faqs

                Frequently asked questions about Jaypirca (pirtobrutinib)

                Is Jaypirca (pirtobrutinib) chemotherapy?
                No, Jaypirca (pirtobrutinib) isn’t a chemotherapy medication. Instead, it’s a targeted therapy. Chemotherapy works by attacking any cell that’s growing quickly, including cancer cells. But Jaypirca (pirtobrutinib) works in a more specific, targeted way. It blocks a protein called Bruton tyrosine kinase (BTK), which stops lymphoma cells from growing or spreading as well.
                How is Jaypirca (pirtobrutinib) different from other Bruton tyrosine kinase (BTK) inhibitors?
                Jaypirca (pirtobrutinib) is the newest BTK inhibitor to receive FDA-approval. It differs from the older BTK inhibitors, such as Imbruvica (ibrutinib) and Calquence (acalabrutinib), based on how it binds to the BTK protein. The older BTK inhibitors all bind to BTK the same way. Unfortunately, many cancer cells have developed resistance to these medications, which means that they might not work as well in fighting cancer. Jaypirca (pirtobrutinib) is unique and binds to BTK in a different way than the others. This means that Jaypirca (pirtobrutinib) might work against cancer cells that have become resistant to one of the older BTK inhibitors.
                What are some common side effects of Jaypirca (pirtobrutinib)?
                One of the most common side effects of Jaypirca (pirtobrutinib) is lower blood cell count. This affects red blood cells (RBCs), white blood cells (WBCs) and platelets. You might not experience any symptoms when you have lower blood cell counts, so your oncology team will order blood tests to check your blood cell counts regularly throughout treatment. This is because having lower blood cell counts can raise your risk of serious problems, including anemia (which can lead to tiredness), serious infections, and bleeding that’s difficult to stop. If your blood cell count levels drop too low, your team might lower your dose of Jaypirca (pirtobrutinib) or ask you to stop treatment for some time to give your blood cell levels a chance to recover. Ask your oncology team if you have specific concerns about this side effect.
                Does Jaypirca (pirtobrutinib) interact with other medications?
                Yes, Jaypirca (pirtobrutinib) can interact with other medications. Some medications, like phenytoin (Dilantin) or carbamazepine (Tegretol), can lower the levels of Jaypirca (pirtobrutinib) in your body and cause it to not work as well to treat cancer. Other medications, like clarithromycin (Biaxin) or diltiazem (Cardizem), can raise the levels of Jaypirca (pirtobrutinib) in your body and might make side effects worse. Your oncology team might ask you to avoid taking certain medications with Jaypirca (pirtobrutinib) to prevent serious interactions. But if that’s not possible, they might adjust your Jaypirca (pirtobrutinib) dose. Don’t start or stop any new medications while taking Jaypirca (pirtobrutinib) without first talking to your healthcare team.
                Does Jaypirca (pirtobrutinib) cause nausea?
                Some people can feel nauseous after starting Jaypirca (pirtobrutinib), but this isn’t a common side effect. If you do experience nausea while taking this medication, contact your oncology care team. If appropriate, they might recommend an antiemetic, such as ondansetron (Zofran) or prochlorperazine (Compazine) to manage that side effect. Your care team can also give you tips for easing nausea, such as avoiding certain foods that might trigger nausea and eating foods that are easier on the stomach, including yogurt, plain pasta, and ginger tea.
                Does Jaypirca (pirtobrutinib) cause hair loss?
                People taking Jaypirca (pirtobrutinib) don’t typically lose their hair. If you do notice hair thinning or loss while taking Jaypirca (pirtobrutinib), talk to your oncologist. There might be other causes they want to look into.
                How long should I take Jaypirca (pirtobrutinib) for?
                You should take Jaypirca (pirtobrutinib) as instructed by your oncologist. How long you take Jaypirca (pirtobrutinib) depends on several factors, such as how well the medication is working to treat your cancer and how well you tolerate the side effects. Your oncologist will tell how well the medication is working based on your symptoms, lab results, and scan results. Don’t stop taking Jaypirca (pirtobrutinib) without first discussing it with your oncology team.
                GoodRxEducationalIcon

                How to save using GoodRx

                Compare Prices
                1. Compare PricesSpecify your dosage and quantity to find out exactly how much you can save.
                Select your free coupon
                2. Select your free couponYou can use the displayed coupon, or compare prices at other pharmacies near you.
                Show coupon to your pharmacist
                3. Show coupon to your pharmacistPresent your printed or electronic coupon when you pick up your prescription.
                Get free couponLearn more
                warings-icon

                What are the risks and warnings for Jaypirca (pirtobrutinib)?

                Jaypirca (pirtobrutinib) can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.

                risk-warning

                Serious infection

                Some people taking Jaypirca (pirtobrutinib) have developed serious infections, including pneumonia and sepsis. Sometimes, the infections can be life-threatening. To lower the risk of serious infections, your oncologist might prescribe antivirals or antibiotics during treatment and ask you to get certain vaccinations before starting Jaypirca (pirtobrutinib). If you do get sick, your oncologist might lower your dose or ask you to stop taking Jaypirca (pirtobrutinib). If you have any symptoms of infection such as fever, chills, or weakness, contact your oncology team right away.

                risk-warning

                Serious bleeding

                • Risk factors: Surgery or procedure

                  Jaypirca (pirtobrutinib) can cause bleeding. The most common symptom is bruising. But rarely, some people have experienced serious bleeding in areas like the brain or gut. You’re at higher risk for bleeding if you’re taking blood thinner medications. Let your oncologist know if you need any type of surgical procedure while you’re taking Jaypirca (pirtobrutinib) because they might recommend you pause the medication for a few days before and after the procedure to prevent bleeding. If you do experience a bleed or bruising that doesn’t go away, your oncologist might lower your dose or ask you to stop taking Jaypirca (pirtobrutinib). If you have any bruising, nosebleeds, blood in your urine or blood in your stool, contact your oncology team right away.

                  risk-warning

                  Lower blood cell count

                  People taking Jaypirca (pirtobrutinib) may develop lower blood cells in their body, including your white blood cells (WBCs), red blood cells (RBCs), and platelets. This can raise your risk for certain problems, such as serious infections, anemia, and bleeding. Your oncologist will monitor your blood cell counts very closely while you’re taking Jaypirca (pirtobrutinib). If your blood cell counts drop too low, then your oncologist might lower your dose or ask you to stop taking Jaypirca (pirtobrutinib). If you have any unexpected bruising, bleeding, or you feel very tired, contact your oncology team right away, since these can be signs of lower blood cell counts.

                  risk-warning

                  Heart rhythm changes

                  • Risk factors: High blood pressure | Heart rhythm problems

                    Rarely, people taking Jaypirca (pirtobrutinib) experienced heart rhythm changes including atrial fibrillation and atrial flutter. Symptoms include abnormal heart beat, feeling dizzy, passing out, and trouble breathing. If you experience any of these, contact your oncology team right away. You might need to pause Jaypirca (pirtobrutinib) while they look into it.

                    risk-warning

                    Risk of new cancers

                    Though uncommon, some people who took Jaypirca (pirtobrutinib) later developed a new cancer, including skin cancers or breast cancers. Make sure you protect your skin from the sun by using sunscreen and clothes that protect your skin. If appropriate, ask your oncology team to show you how to perform self breast exams to check for breast cancer. Your oncologist will monitor you for new cancers, but you should let them know if you notice any changes in your breast or skin.

                    risk-warning

                    Liver problems

                    Though rare, some people who took Jaypirca (pirtobrutinib) developed serious liver problems. Your oncology team will order blood tests to check your liver health. If so, they might ask you to pause or stop taking Jaypirca (pirtobrutinib) altogether. Tell your care team right away if you notice symptoms of liver problems, including tiredness, stomach pain, and yellowing of the skin or whites of the eye.

                    risk-warning

                    Harm to unborn baby

                    Jaypirca (pirtobrutinib) hasn’t been studied in human pregnancy, but based on animal studies and the way the medication works, it can cause harm to an unborn baby. If you’re a female able to have babies, your oncologist might ask you to take a pregnancy test before you start treatment to make sure you’re not pregnant. You should use effective birth control while taking Jaypirca (pirtobrutinib) and for 1 week after the last dose. If you become pregnant while taking Jaypirca (pirtobrutinib), contact your oncology team right away.

                    dosage

                    Jaypirca (pirtobrutinib) dosage forms

                    Typical dosing for Jaypirca (pirtobrutinib)

                    The usual dose of Jaypirca (pirtobrutinib) is 200 mg by mouth once a day.

                    Your dose might be different if you have kidney problems or if you’re taking medications that might interact with Jaypirca (pirtobrutinib).

                    drug-cost

                    How much does Jaypirca (pirtobrutinib) cost?

                    To access savings, use a GoodRx coupon and pay just a fraction of the retail price.
                    Jaypirca (brand)
                    GoodRx lowest price

                    $22957.34

                    (save 8.88%)
                    View prices & coupons
                    alternatives

                    What are alternatives to Jaypirca (pirtobrutinib)?

                    There are a number of medications that your doctor can prescribe in place of Jaypirca (pirtobrutinib). Compare a few possible alternatives below.
                    Jaypirca (pirtobrutinib)
                    Used for:
                    $22957.34 Lowest GoodRx priceView Prices
                    Calquence (acalabrutinib)
                    Used for:

                    • Mantle cell lymphoma (MCL)

                    • Chronic lymphocytic leukemia (CLL)

                    • Small lymphocytic lymphoma (SLL)

                    View Prices
                    Brukinsa (zanubrutinib)
                    Used for:
                    View Prices
                    images

                    Jaypirca (pirtobrutinib) images

                    Blue Round 7026 And Lilly 100 - Jaypirca 100mg Tablet
                    This medicine is Blue, Round Tablet Imprinted With "7026" And "Lilly 100".Blue Round 7026 And Lilly 100 - Jaypirca 100mg Tablet

                    Get savings updates for Jaypirca (pirtobrutinib)

                    Receive price alerts, news, and other messages from GoodRx about Jaypirca (pirtobrutinib) and other healthcare topics and relevant savings offers.

                    By signing up, I agree to GoodRx's Terms and Privacy Policy, and to receive marketing messages from GoodRx.

                    References

                    Best studies we found

                    Alu, A., et al. (2022). BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: Mechanisms and clinical studies. Journal of Hematology & Oncology.

                    American Cancer Society. (2019). Targeted therapy safety.

                    American Cancer Society. (2021). How targeted therapies are used to treat cancer.

                    View All References (13)

                    Centers for Disease Control and Prevention. (n.d.). What you need to know: Neutropenia and risk for infection.

                    Eli Lilly and Company. (2024). Jaypirca- pirtobrutinib tablet, coated [package insert]. DailyMed.

                    Lymphoma Research Foundation. (n.d.). What is lymphoma?

                    Mato, A. R., et al. (2023). Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia. The New England Journal of Medicine.

                    National Cancer Institute. (n.d.). BTK inhibitor.

                    National Cancer Institute. (n.d.). Mantle cell lymphoma.

                    National Cancer Institute. (2022). Targeted therapy to treat cancer.

                    National Cancer Institute. (2024). Nausea and vomiting and cancer treatment.

                    National Comprehensive Cancer Network. (2021). Anemia and neutropenia: Low red and white blood cell counts.

                    Rozkiewicz, D., et al. (2023). Bruton's tyrosine kinase inhibitors (BTKIs): Review of preclinical studies and evaluation of clinical trials. Molecules.

                    Thompson, P. A., et al. (2023). Pirtobrutinib: A new hope for patients with BTK inhibitor-refractory lymphoproliferative disorders. Blood.

                    Wang, M. L., et al. (2023). Pirtobrutinib in covalent Bruton tyrosine kinase inhibitor pretreated mantle-cell lymphoma. Journal of Clinical Oncology.

                    Ziccardi, M. R., et al. (2022). Atrial flutter. StatPearls.

                    GoodRx Health has strict sourcing policies and relies on primary sources such as medical organizations, governmental agencies, academic institutions, and peer-reviewed scientific journals. Learn more about how we ensure our content is accurate, thorough, and unbiased by reading our editorial guidelines.
                    Was this page helpful?

                    Browse medications

                    View All

                    Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.